Effects of Metformin and Rosiglitazone, Alone and in Combination, in Nonobese Women With Polycystic Ovary Syndrome and Normal Indices of Insulin Sensitivity

Baillargeon, Jean-Patrice; Jakubowicz, Daniela; Iuomo, Maria J.; Jakubowicz, Salomon; Nestler, John E.

doi:10.1097/01.ogx.0000156098.76251.15

Cited by 45 publications

(71 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cumulative ovulation rate over 3 cycles of therapy was significantly higher in the rosiglitazone group 81.8% versus 55.2% in CC only group in agreement with other studies [11][12][13][14][15][16]. More than 75 % of the PCOS women in this study were obese and the remaining were overweight which adds additional burden of IR secondary to their adiposity.…”

Section: Discussionsupporting

confidence: 93%

A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome

Mohsen

2011

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome

Mohsen

2011

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…Improving insulin sensitivity with these drugs is associated with a decrease in circulating androgen levels, improved ovulation rate, and improved glucose tolerance. [29][30][31][32] However the concern about hepatotoxicity, cardiovascular risk, weight gain, and the pregnancy category C have limited the use of these drugs in women with PCOS.…”

Section: Biguanidementioning

confidence: 98%

Polycystic ovarian syndrome

Madnani

Khan

Chauhan

et al. 2013

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

Polycystic ovarian syndrome (PCOS) is a "multispeciality" disorder suspected in patients with irregular menses and clinical signs of hyperandrogenism such as acne, seborrhoea, hirsutism, irregular menses, infertility, and alopecia. Recently, PCOS has been associated with the metabolic syndrome. Patients may develop obesity, insulin resistance, acanthosis nigricans, Type 2 diabetes, dyslipidemias, hypertension, non-alcoholic liver disease, and obstructive sleep apnoea. Good clinical examination with hematological and radiological investigations is required for clinical evaluation. Management is a combined effort involving a dermatologist, endocrinologist, gynecologist, and nutritionist. Morbidity in addition includes a low "self image" and poor quality of life. Long term medications and lifestyle changes are essential for a successful outcome. This article focuses on understanding the normal and abnormal endocrine functions involved in the pathogenesis of PCOS. Proper diagnosis and management of the patient is discussed.

show abstract

“…10,11 Thiazolidinediones have also been shown to decrease androgen levels, improve ovulation, and reduce progression to overt T2DM in patients with PCOS and impaired glucose tolerance (IGT). [12][13][14] Metformin (N, N-dimethylimidodicarbonimidic diamide) is now thought to be of therapeutic value directly and/or indirectly in the management of PCOS. 15 It is the first-line drug of choice for the treatment of T2DM, particularly in overweight and obese people and those with abnormal kidney function.…”

Section: Introductionmentioning

confidence: 99%

Effect of Treatment with Metformin on Omentin-1, Ghrelin and other Biochemical, Clinical Features in PCOS Patients

Shaker¹

2010

OMJ

View full text Add to dashboard Cite

There was a significant an increase in omentin1: insulin ratio, omentin1: HOMA ratio and omentin1: HOMA ß-cell% ratio. These results in the present study are shown the first time, these factors may be useful in following improvements in insulin sensitivity in subjects with polycystic ovary syndrome or obesity treated with insulin sensitizers. Further studies are needed to certify these factors in other populations with these treatment or with other insulin sensitizers or when treated with diet and exercise.

show abstract

Effects of Metformin and Rosiglitazone, Alone and in Combination, in Nonobese Women With Polycystic Ovary Syndrome and Normal Indices of Insulin Sensitivity

Cited by 45 publications

References 0 publications

A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome

A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome

Polycystic ovarian syndrome

Effect of Treatment with Metformin on Omentin-1, Ghrelin and other Biochemical, Clinical Features in PCOS Patients

Contact Info

Product

Resources

About